King's College London

Research portal

Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia

Research output: Contribution to journalArticle

Standard

Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. / Solmi, Marco; Veronese, Nicola; Thapa, Nita; Facchini, Silvia; Stubbs, Brendon; Fornaro, Michele; Carvalho, André F; Correll, Christoph U.

In: CNS SPECTRUMS, 09.02.2017, p. 1-12.

Research output: Contribution to journalArticle

Harvard

Solmi, M, Veronese, N, Thapa, N, Facchini, S, Stubbs, B, Fornaro, M, Carvalho, AF & Correll, CU 2017, 'Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia', CNS SPECTRUMS, pp. 1-12. https://doi.org/10.1017/S1092852916000638

APA

Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., Carvalho, A. F., & Correll, C. U. (2017). Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS SPECTRUMS, 1-12. https://doi.org/10.1017/S1092852916000638

Vancouver

Solmi M, Veronese N, Thapa N, Facchini S, Stubbs B, Fornaro M et al. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS SPECTRUMS. 2017 Feb 9;1-12. https://doi.org/10.1017/S1092852916000638

Author

Solmi, Marco ; Veronese, Nicola ; Thapa, Nita ; Facchini, Silvia ; Stubbs, Brendon ; Fornaro, Michele ; Carvalho, André F ; Correll, Christoph U. / Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. In: CNS SPECTRUMS. 2017 ; pp. 1-12.

Bibtex Download

@article{8bdde9b948f043c2bc1c65f1f0f1b0ea,
title = "Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia",
abstract = "OBJECTIVE: Our aim was to perform an updated systematic review and meta-analysis on the efficacy and safety of adjunctive minocycline as a treatment of schizophrenia.METHODS: We conducted a PubMed/Scopus database search from inception to 3 February 2016 for randomized, placebo-controlled trials (RCTs), open non-randomized studies, and case reports/series evaluating minocycline in patients with schizophrenia. Random-effects meta-analysis of positive, negative, depressive, and cognitive symptom rating scales, discontinuation and adverse effects rates calculating standardized mean difference (SMD), and risk ratios±95% confidence intervals (CI 95%) were calculated.RESULTS: Six RCTs were eligible (minocycline n=215, placebo n=198) that demonstrated minocycline's superiority versus placebo for reducing endpoint Positive and Negative Syndrome Scale (PANSS) total scores (SMD=-0.59; CI 95%=[1.15, -0.03]; p=0.04), negative (SMD=-0.76; CI 95%=[-1.21, -0.31]; p=0.001); general subscale scores (SMD=-0.44; CI 95%=[-0.88, -0.00]; p=0.05), Clinical Global Impressions scores (SMD=-0.50; CI 95%=[-0.78, -0.22]; p<0.001); and executive functioning (SMD=0.22; CI 95%=[0.01, 0.44]; p=0.04). Endpoint PANSS positive symptom scores (p=0.13), depression rating scale scores (p=0.43), attention (p=0.47), memory (p=0.52), and motor speed processing (p=0.50) did not significantly differ from placebo, before execution of a trim-and-fill procedure. Minocycline did not differ compared to placebo on all-cause discontinuation (p=0.56), discontinuation due to inefficacy (p=0.99), and intolerability (p=0.51), and due to death (p=0.32). Data from one open-label study (N=22) and three case series (N=6) were consistent with the metaanalytic results.CONCLUSIONS: Minocycline appears to be an effective adjunctive treatment option in schizophrenia, improving multiple relevant disease dimensions. Moreover, minocycline has an acceptable safety and tolerability profile. However, more methodologically sound and larger RCTs remain necessary to confirm and extend these results.",
author = "Marco Solmi and Nicola Veronese and Nita Thapa and Silvia Facchini and Brendon Stubbs and Michele Fornaro and Carvalho, {Andr{\'e} F} and Correll, {Christoph U}",
year = "2017",
month = feb,
day = "9",
doi = "10.1017/S1092852916000638",
language = "English",
pages = "1--12",
journal = "CNS SPECTRUMS",
issn = "1092-8529",
publisher = "Cambridge University Press",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia

AU - Solmi, Marco

AU - Veronese, Nicola

AU - Thapa, Nita

AU - Facchini, Silvia

AU - Stubbs, Brendon

AU - Fornaro, Michele

AU - Carvalho, André F

AU - Correll, Christoph U

PY - 2017/2/9

Y1 - 2017/2/9

N2 - OBJECTIVE: Our aim was to perform an updated systematic review and meta-analysis on the efficacy and safety of adjunctive minocycline as a treatment of schizophrenia.METHODS: We conducted a PubMed/Scopus database search from inception to 3 February 2016 for randomized, placebo-controlled trials (RCTs), open non-randomized studies, and case reports/series evaluating minocycline in patients with schizophrenia. Random-effects meta-analysis of positive, negative, depressive, and cognitive symptom rating scales, discontinuation and adverse effects rates calculating standardized mean difference (SMD), and risk ratios±95% confidence intervals (CI 95%) were calculated.RESULTS: Six RCTs were eligible (minocycline n=215, placebo n=198) that demonstrated minocycline's superiority versus placebo for reducing endpoint Positive and Negative Syndrome Scale (PANSS) total scores (SMD=-0.59; CI 95%=[1.15, -0.03]; p=0.04), negative (SMD=-0.76; CI 95%=[-1.21, -0.31]; p=0.001); general subscale scores (SMD=-0.44; CI 95%=[-0.88, -0.00]; p=0.05), Clinical Global Impressions scores (SMD=-0.50; CI 95%=[-0.78, -0.22]; p<0.001); and executive functioning (SMD=0.22; CI 95%=[0.01, 0.44]; p=0.04). Endpoint PANSS positive symptom scores (p=0.13), depression rating scale scores (p=0.43), attention (p=0.47), memory (p=0.52), and motor speed processing (p=0.50) did not significantly differ from placebo, before execution of a trim-and-fill procedure. Minocycline did not differ compared to placebo on all-cause discontinuation (p=0.56), discontinuation due to inefficacy (p=0.99), and intolerability (p=0.51), and due to death (p=0.32). Data from one open-label study (N=22) and three case series (N=6) were consistent with the metaanalytic results.CONCLUSIONS: Minocycline appears to be an effective adjunctive treatment option in schizophrenia, improving multiple relevant disease dimensions. Moreover, minocycline has an acceptable safety and tolerability profile. However, more methodologically sound and larger RCTs remain necessary to confirm and extend these results.

AB - OBJECTIVE: Our aim was to perform an updated systematic review and meta-analysis on the efficacy and safety of adjunctive minocycline as a treatment of schizophrenia.METHODS: We conducted a PubMed/Scopus database search from inception to 3 February 2016 for randomized, placebo-controlled trials (RCTs), open non-randomized studies, and case reports/series evaluating minocycline in patients with schizophrenia. Random-effects meta-analysis of positive, negative, depressive, and cognitive symptom rating scales, discontinuation and adverse effects rates calculating standardized mean difference (SMD), and risk ratios±95% confidence intervals (CI 95%) were calculated.RESULTS: Six RCTs were eligible (minocycline n=215, placebo n=198) that demonstrated minocycline's superiority versus placebo for reducing endpoint Positive and Negative Syndrome Scale (PANSS) total scores (SMD=-0.59; CI 95%=[1.15, -0.03]; p=0.04), negative (SMD=-0.76; CI 95%=[-1.21, -0.31]; p=0.001); general subscale scores (SMD=-0.44; CI 95%=[-0.88, -0.00]; p=0.05), Clinical Global Impressions scores (SMD=-0.50; CI 95%=[-0.78, -0.22]; p<0.001); and executive functioning (SMD=0.22; CI 95%=[0.01, 0.44]; p=0.04). Endpoint PANSS positive symptom scores (p=0.13), depression rating scale scores (p=0.43), attention (p=0.47), memory (p=0.52), and motor speed processing (p=0.50) did not significantly differ from placebo, before execution of a trim-and-fill procedure. Minocycline did not differ compared to placebo on all-cause discontinuation (p=0.56), discontinuation due to inefficacy (p=0.99), and intolerability (p=0.51), and due to death (p=0.32). Data from one open-label study (N=22) and three case series (N=6) were consistent with the metaanalytic results.CONCLUSIONS: Minocycline appears to be an effective adjunctive treatment option in schizophrenia, improving multiple relevant disease dimensions. Moreover, minocycline has an acceptable safety and tolerability profile. However, more methodologically sound and larger RCTs remain necessary to confirm and extend these results.

U2 - 10.1017/S1092852916000638

DO - 10.1017/S1092852916000638

M3 - Article

C2 - 28181901

SP - 1

EP - 12

JO - CNS SPECTRUMS

JF - CNS SPECTRUMS

SN - 1092-8529

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454